Lymphoma
Lymphoma
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
60
Clinical Trials
Lymphoma
Phase I
Accepting Patients
nct/study# NCT04231747 / CC-97540-NHL-001
A Phase 1, Multicenter, Open-Label Study Of CC-97540, CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
Learn More
Lymphoma
Phase II
Accepting Patients
nct/study# NCT03646123 / SGN35-027
Multiple Part Clinical Trial Of Brentuximab Vedotin In Classical Hodgkin Lymphoma Subjects
Learn More
Lymphoma
Phase I
Accepting Patients
nct/study# NCT03930953 / CC-99282-NHL-001
A Phase 1, Multi-Center, Open-Label Study To Assess The Safety, Pharmacokinetics, And Preliminary Efficacy Of An Orally Available Small Molecule, CC-99282, Alone And In Combination With Rituximab In Subjects With Relapsed Or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Learn More
Lymphoma
Phase II
Accepting Patients
nct/study# NCT04268706 / TESSCAR001
A Phase 2 Multi-Center Study Evaluating The Safety And Efficacy Of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) In Adult And Pediatric Patients With Relapsed Or Refractory CD30 Positive Classical Hodgkin Lymphoma (CHARIOT TESSCAR001)
Learn More
Lymphoma
Phase I
Accepting Patients
nct/study# NCT04277637 / BGB-11417-101
A Phase 1/1b Open-Label Dose Escalation And Expansion Study Of Bcl-2 Inhibitor BGB-11417 In Patients With Mature B-Cell Malignancies
Learn More
Lymphoma
Phase I
Accepting Patients
nct/study# NCT02663518 / TTI-621-01
A Phase 1a/1b Dose Escalation And Expansion Trial Of TTI-621, A Novel Biologic Targeting CD47, In Subjects With Relapsed Or Refractory Hematologic Malignancies And Selected Solid Tumors
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.